Isocitrate dehydrogenase 1 R132H neoepitope (IDH1R132H neoepitope)

The **IDH1R132H neoepitope** is a tumor-specific mutant peptide generated by the R132H point mutation in the isocitrate dehydrogenase 1 (IDH1) enzyme. This mutation results in a neomorphic enzyme activity that produces the oncometabolite D-2-hydroxyglutarate, leading to wide-ranging epigenetic and metabolic disturbances that drive tumorigenesis. The neoepitope generated by this mutation can be presented by MHC class II molecules, making it a promising immunotherapeutic target. Peptide vaccines targeting the IDH1R132H neoepitope are in clinical trials for glioma and have demonstrated the induction of specific T-helper immune responses and early safety. The IDH1R132H mutation is a driver in several cancers, particularly astrocytomas and other gliomas, and has also been therapeutically targeted by small molecule IDH1 inhibitors[1][2][3][5].

Other names

IDH1(R132H) neoepitopeMutant IDH1 neoepitopeIDH1-mutant neoepitope (R132H)IDH1R132H peptide

IDH1 inhibitors: block the neomorphic catalytic activity of mutant IDH1, reducing oncometabolite (D-2HG) production[2][3] Peptide vaccine: induces neoantigen-specific CD4+ T cell response, leading to immune attack against tumor cells presenting the IDH1R132H neoepitope on MHC class II[1][3]